Research Study

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
Principal Investigator 
Kenneth Gin

Overview

Body Locations and Systems 
ClinicalTrials.gov# 
NCT02787044
Status 
Recruiting
Study Start/End 
Sep 8, 2016 to Jul 30, 2020
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Shirley Lim, Research Coordinator
Phone 
604-875-4065
Email Address 
shirley.lim@vch.ca
Purpose of Study 

INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.